Research Topics
| Eric M RudermanSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment advances in psoriatic arthritisEric M Ruderman
Northwestern University Feinberg School of Medicine, 675 North St Clair, Suite 14 100, Chicago, IL 60611, USA
Curr Rheumatol Rep 7:313-8. 2005..Recent data on potential future therapies is discussed as well, along with data on the mechanisms of current therapies that may have relevance for future treatment approaches...- Drug Insight: abatacept for the treatment of rheumatoid arthritisEric M Ruderman
Division of Rheumatology, Northwestern University Feinberg School of Medicine, 675 North St Clair Street, Chicago, IL 60611, USA
Nat Clin Pract Rheumatol 2:654-60. 2006..This article discusses the proposed mechanism of action of abatacept and reviews the data from phase II and phase III clinical trials on the safety and efficacy of this drug in RA... - The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisEric M Ruderman
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Arthritis Res Ther 7:S21-5. 2005..This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease... - Evaluation and management of psoriatic arthritis: the role of biologic therapyEric M Ruderman
Division of Rheumatology, Feinberg School of Medicine, Northwestern University, 300 East Chicago Avenue, Ward 3 315, Chicago, IL 60611, USA
J Am Acad Dermatol 49:S125-32. 2003..The newer biologic antirheumatic drugs appear to combine greater efficacy of treatment with significantly less toxicity by targeting specific mediators involved in the pathogenesis of PsA... - Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologistEric M Ruderman
Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, McGaw 2300, Chicago, IL 60611, USA
Dermatol Clin 22:477-86, x. 2004..Treatment includes both traditional immunomodulatory agents as well as the recently available biologic response modifiers... - Current and future pharmaceutical therapy for rheumatoid arthritisEric M Ruderman
Northwestern University of Feinburg School of Medicine, USA
Curr Pharm Des 11:671-84. 2005..The widespread use of newer agents, however, along with more aggressive use of existing therapies, appears to limit disease progression very effectively, and should lead to better long-term outcomes for these patients... - Current management of rheumatoid arthritisSiddharth Tambar
Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Manag Care Interface 20:18-24. 2007..None of these therapies represents a cure for RA; however, the availability and the efficacy of multiple treatments has made remission of the disease a realistic target... - Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destructionSakeba N Issa
Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, USA
Postgrad Med 116:14-6, 21-4. 2004..They review the steps toward its diagnosis and urge that treatment be started promptly--to both contain disease and reduce joint destruction as soon as possible... - Novel TNF antagonists for the treatment of rheumatoid arthritisLaisvyde Statkute
Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Expert Opin Investig Drugs 19:105-15. 2010.... - Interleukin 6 inhibition - RA and beyondRobert S Woodrick
Northwestern University Feinberg School of Medicine Chicago, Illinois, USA
Bull NYU Hosp Jt Dis 69:225-9. 2011..Finally, there is interest in the potential of IL-6 inhibition in other diseases, although meaningful data has not yet become available... - Intracellular signal pathways: potential for therapiesMelissa Mavers
Department of Medicine, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, McGaw Pavilion, Chicago, IL 60611, USA
Curr Rheumatol Rep 11:378-85. 2009..The success of many clinical trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available... - Anti-interleukin-6 therapy in rheumatoid arthritisRobert Woodrick
Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois USA
Bull NYU Hosp Jt Dis 68:211-7. 2010..Adverse events seen with tocilizumab therapy are also reviewed... - More than just B-cell inhibitionEric M Ruderman
Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, 240 E, Huron Street, McGaw M300, Chicago, IL 60611, USA
Arthritis Res Ther 13:125. 2011..However, other kinase inhibitors have failed to transition from animal models to human therapy, so it remains to be seen whether a Btk inhibitor will have a role in the RA treatment armamentarium... - Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyMichael E Weinblatt
Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Arthritis Rheum 58:1921-30. 2008.... - The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approachKenneth B Gordon
Division of Dermatology, Evanston Northwestern Healthcare, Skokie, Illinois 60077, USA
J Am Acad Dermatol 54:S85-91. 2006..Finally, a conceptual model for the therapy of psoriasis and psoriatic arthritis, the Four Quadrant Model, is presented as a simplified framework to use when considering treatment for psoriatic disease... - Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease
Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington 98104, USA
Arthritis Rheum 52:3279-89. 2005..Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA)... - Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialJoel M Kremer
The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
Ann Intern Med 137:726-33. 2002..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate... - Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient careEric M Ruderman
Am J Manag Care 8:S171-80. 2002..Etanercept has been shown to be well tolerated, even for long-term use, and is potentially superior to disease-modifying antirheumatic drugs...